Trial Profile

A registration directed Phase 1/2 clinical study of GP-2250 in ovarian cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Misetionamide (Primary)
Indications Ovarian cancer
Focus Proof of concept; Registrational; Therapeutic Use
Sponsors Panavance Therapeutics

Most Recent Events

14 Aug 2024 According to a Panavance Therapeutics media release, Company had a pre-IND meeting with the FDA to discuss our ovarian cancer clinical and regulatory plan in May.
08 Nov 2022 New trial record
02 Nov 2022 According to Panavance therapeutics media release, this study is expected to start in the second half of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com